AbbVie (ABBV) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard New custom dashboard
Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
06B12B19B25B31B38B44B50BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
01B2B3B4B6B7B8B9BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

EBITDA

EBITDA
01B2B3B4B5B6B7B8BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

EPS

EPSEPS Diluted
011223445Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue Variation (%)

Revenue Variation
-20-15-10-505101520Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Income Variation (%)

Gross Profit VariationOperating Income Variation
03875112150188225262300Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue YoY Variation (%)

Revenue YoY Variation
02581012151820Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
01020304050607080Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Price-to-Earning Ratio

P/E Ratio
088175262350438525612700Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
012253850627588100Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
02B5B8B10B12B15B18B20BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
02B5B8B10B12B15B18B20BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Cash Flow to Debt Ratio

Cash At End Of Period
01B2B4B5B6B8B9B10BQ2 2025Q3 2025Q4 2025Q1 2026
Balance Sheet

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
01B2B3B4B5B6B7B8BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Quick Ratio

Total AssetsTotal Liabilities
038B75B112B150B188B225B262B300BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
025B50B75B100B125B150B175B200BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
025B50B75B100B125B150B175B200BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Total Liabilities

Total Stockholders Equity
-7B-6B-5B-4B-3B-3B-2B-875M1Q2 2025Q3 2025Q4 2025Q1 2026

Shareholders Equity

Debt To Equity
-500-437-375-312-250-187-124-621Q2 2025Q3 2025Q4 2025Q1 2026

Asset Composition

Cash And Cash EquivalentsShort Term Investments
01B2B4B5B6B8B9B10BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Debt Structure

Short Term DebtLong Term Debt
010B20B30B40B50B60B70B80BQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Key Metrics

AbbVie (ABBV) quarterly earnings & revenue

AbbVie (ABBV) reported revenue of $16.99B for Q2 2026, up 10.2% year-over-year, with net income of $3.62B and diluted EPS of $2.04.

Over the last four reported quarters, AbbVie generated $64.39B in revenue and $6.32B in net income.

AbbVie's next earnings report is scheduled for July 31, 2026 before market open; analysts estimate EPS of $3.87.

AbbVie quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q2 2026$16.99B+10.2%$3.62B$2.04
Q1 2026$15.00B+12.4%$699.00M$0.39
Q4 2025$16.62B+10.0%$1.82B$1.02
Q3 2025$15.78B+9.1%$186.00M$0.10
Q2 2025$15.42B+6.6%$938.00M$0.53
Q1 2025$13.34B+8.4%$1.29B$0.72
Q4 2024$15.10B+5.6%$-22.00M$-0.02
Q3 2024$14.46B+3.8%$1.56B$0.88

📈 Analysts estimate ABBV EPS of $3.87 for the upcoming quarter. See AbbVie revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

AbbVie (ABBV) — frequently asked questions

When does AbbVie (ABBV) report earnings next?

AbbVie is expected to report earnings on July 31, 2026 before market open. Analysts estimate EPS of $3.87.

What was ABBV's revenue last quarter?

AbbVie reported revenue of $16.99B in Q2 2026, up 10.2% from the same quarter a year earlier.

What was ABBV's EPS last quarter?

AbbVie reported diluted EPS of $2.04 in Q2 2026.

Is AbbVie profitable?

AbbVie is currently profitable, with $6.32B in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)